Optimizing the Delivery of Short-Lived Alpha Particle-Emitting Isotopes to Solid Tumors
The underlying hypothesis of this project was that optimal alpha emitter-based radioimmunotherapy (RAIT) could be achieved by pairing the physical half-life of the radioisotope to the biological half-life of the targeting vehicle. The project had two specific aims. The first aim was to create and optimize the therapeutic efficacy of 211At-SAPS-C6.5 diabody conjugates. The second aim was to develop bispecific-targeting strategies that increase the specificity and efficacy of alpha-emitter-based RAIT. In the performance of the first aim, we created 211At-SAPS-C6.5 diabody conjugates that specifically targeted the HER2 tumor associated antigen. In evaluating these immunoconjugates we determined that they were capable of efficient tumor targeting and therapeutic efficacy of established human tumor xenografts growing in immunodeficient mice. We also determined that therapeutic doses were associated with late renal toxicity, likely due to the role of the kidneys in the systemic elimination o f these agents. We are currently performing more studies focused on better understanding the observed toxicity. In the second aim, we successfully generated bispecific single-chain Fv (bs-scFv) molecules that co-targeted HER2 and HER3 or HER2 and HER4. The in vitro kinetics and in vivo tumor-targeting properties of these molecules were evaluated. These studies revealed that the bs-scFv molecules selectively localized in vitro on tumor cells that expressed both antigens and were capable of effective tumor localization in in vivo studies.
- Research Organization:
- Fox Chase Cancer Center (US)
- Sponsoring Organization:
- (US)
- DOE Contract Number:
- FG02-01ER63190
- OSTI ID:
- 834981
- Report Number(s):
- DOE/ER/63190-1; 27757; TRN: US0502905
- Resource Relation:
- Other Information: PBD: 24 Nov 2004
- Country of Publication:
- United States
- Language:
- English
Similar Records
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma